/ 2 items

#DYN↓

Featured/ RNA/ 10/27/2025 · 6:53 AM

Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan

Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.

DYN/ 10/10/2025 · 8:45 AM

Despite Positive DYNE-101 Data, Oppenheimer Steps to the Sidelines on Dyne Therapeutics Due to Valuation and Safety Caution

Oppenheimer downgrades Dyne Therapeutics to Perform from Outperform, maintaining $13 price target. New Phase 1/2 data shows promise, but valuation concerns prompt caution.